Expert Discusses Living With Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy affects many patients with cancer, so CURE spoke with an expert about coping strategies for those who have developed this condition.
BY BRIELLE URCIUOLI @Brielle_U
PUBLISHED: JULY 24, 2017
Many patients who receive chemotherapy to treat their cancer develop chemotherapy-induced peripheral neuropathy (CIPN), a condition that often presents itself as numbness, tingling or loss of feelings in the hands and feet.

CIPN can affect a patient’s daily activities long after treatment ends, but there are a number of resources — such as seeing a physical or occupational therapist — that can help manage the condition. CURE spoke to Mackenzi Pergolotti, Ph.D., OTR/L, assistant professor in the Department of Occupational Therapy at Colorado State University. Pergolotti, who focuses much of her research on cancer rehabilitation, answered some of the questions that CURE readers had to ask.

What is chemotherapy-induced peripheral neuropathy, and about what percentage of patients are affected by it?

Chemotherapy-induced peripheral neuropathy, or CIPN for short, can affect up to 90 percent of survivors who receive neuro-toxic chemotherapy (e.g., cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, vincristine, vinblastine among others). Peripheral neuropathy is a set of different symptoms that occur when the nerves farthest from the brain and spinal cord, such as the nerves in hands and feet, are damaged.

Most often, CIPN occurs in both hands or both feet and moves up the limbs. In cancer survivors who receive neuro-toxic chemotherapies, and nerve damage occurs, symptoms can include:
  • pain
  • numbness and tingling
  • loss of feeling in hands and feet
  • hot or cold sensitivities
  • trouble swallowing
  • constipation
  • muscle weakness
  • increasing risk of falling due to impairments in balance
Survivors who have CIPN may notice difficulty buttoning shirts, zipping up pants, picking up drinks and opening jars, or in some cases, debilitating pain.

Once developed, is the condition permanent?

It depends. Some survivors are able to recover from CIPN, but for others, the damage can be permanent. It can depend on age and other conditions survivors may have, like diabetes, or how often and how long the chemotherapy was given.

Are there any other conditions related to neuropathy that may emerge later on down the road?

If CIPN remains an issue, related conditions could be balance issues, trouble breathing, constipation, difficulty urinating, and even a decrease in blood pressure. However, once the toxic chemotherapy is stopped, the body may heal and prevent serious or long-term issues.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
The Logistics of Multigene Panel Testing in Breast Cancer
Generally, health insurance covers the cost of genetic testing recommended by a physician. However, some patients who had BRCA testing in the past have had trouble getting reimbursed for a follow-up panel test. The outof- pocket cost for a single panel test can be up to $5,000, although lower-cost tests are available.
Young Patients With Cancer Don't Always Get the Info They Need
When treated for cancer, young patients don’t always get the information they need from doctors.
Immunotherapy Offers New Optimism for Patients With Merkel Cell Carcinoma
Although chemotherapy has been used to treat patients with Merkel cell carcinoma, immunotherapy agents show great promise, according to findings presented at the 2017 World Congress of Melanoma.
Related Videos
Preserving Eyebrows During Chemotherapy Treatment
Renata Marie Vestevich, founder and developer of Essential Eyebrow Solution (EES), discusses how this topical solution may be able to help patients keep their eyebrow hair while undergoing chemotherapy.
Does Age Affect Cancer Genomics?
Garrett Frampton, associate director of Cancer Genomics at Foundation Medicine, discusses recent research about genetic mutations that are more common in certain age groups.  
Facing Advanced Cancer's Struggles With CALM
Gary Rodin, M.D., head of the Department of Supportive Care at Princess Margaret Cancer Centre, in Toronto, Canada, discusses CALM, an intervention designed to help patients with advanced-stage cancer cope and talk about their concerns.
x
//For side ad protocol